HLI Researcher Named one of Vancouver's Top 40 Under 40
Providence Heart + Lung Institute researcher, Dr. David Granville has been named one of Vancouver's Top 40 Under 40. The award was founded by Business in Vancouver to honour corporate leaders, entrepreneurs and non-profit leaders in British Columbia who have reached a significant level of success before the age of age 40.
Dr. Granville, 38, is a Principal Investigator at the Providence Heart + Lung Institute at St. Paul's Hospital, and an Associate Professor in UBC's Faculty of Medicine.
His current research focuses on understanding and developing new treatments for cardiovascular conditions including aneurysms, atherosclerosis and heart attacks.
Recently, Dr. Granville found that reducing the activity of a protein-degrading enzyme, known as Granzyme B, could reduce blood vessel degeneration that is associated with many age-related cardiovascular conditions, including the progression and rupturing of aneurysms, which is often fatal. These discoveries have lead to the incorporation of a UBC spin-off company, viDA Therapeutics, Inc., of which Dr. Granville is a Founder and Chief Scientific Officer.
To read more click here.
Dr. David Granville